Sunshine Heart (NASDAQ:SSH) is developing a medical device that could revolutionize how Class III/IV Congestive Heart Failure (CHF) patients are treated. The medical device is called C-Pulse, and was invented by the co-founder of the company, Dr.
Sunshine Heart, Inc. (NASDAQ:SSH) announced today the pricing of its previously announced offering of 3,810,000 shares of its common stock at a price to the public of $10.50 per share in an underwritten public offering to raise $40M.
The Sunshine Heart (NASDAQ:SSH) C-Pulse system is a medical device to treat congestive heart failure by assisting the natural heart's pumping function. To further explain: The C-Pulse system is not blood-contacting and does not take over from the heart.
I have been asked why I write about Sunshine Heart (NASDAQ:SSH) C-Pulse. My overriding objective is to create awareness of this new C-Pulse technology and provide knowledge about the benefits to any and all persons, including physicians and patients, ...